INDICATION & LIMITATION OF USE
DESCOVY® for HIV-1 pre-exposure prophylaxis (PrEP) is indicated in at-risk adults and adolescents (≥35 kg) to reduce the risk of sexually acquired HIV-1 infection, excluding individuals at risk from receptive vaginal sex. HIV-1–negative status must be confirmed immediately prior to initiation.
Limitation of Use: DESCOVY FOR PrEP® is not indicated in individuals at risk of HIV-1 from receptive vaginal sex because effectiveness in this population has not been evaluated.
Please see below for Important Safety Information for DESCOVY.
DESCOVY®: Simple dosing with the smallest pill for PrEP1,2
DESCOVY® (FTC/TAF)
(emtricitabine 200 mg/tenofovir alafenamide 25 mg) tablets
TRUVADA® (FTC/TDF)
(emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) tablets
Pills shown are not actual size. DESCOVY actual size is 13 mm W x 6 mm H x 4 mm D. TRUVADA actual size is 19 mm W x 9 mm H x 7 mm D.
Please see full Prescribing Information for TRUVADA, including BOXED WARNING.
The overall
#1
prescribed
PrEP medication
by infectious disease specialists
There’s no generic version of DESCOVY FOR PrEP®.3
| DESCOVY Packaging | NDC Number |
|---|---|
| Bottle | 61958-2002-1 |
| DESCOVY® DayTrackerTM pack | 61958-2002-2 |
Source: IQVIA® LAAD Weekly, 06/26/2020 through 08/04/2023.*
*This information is an estimate derived from the use of information under license from the following IQVIA information service: IQVIA Longitudinal Access and Adjudication Data (LAAD) Weekly, for the period week ending (WE) 01/10/2020 through WE 08/04/2023. IQVIA expressly reserves all rights, including rights of copying, distribution, and republication.
Why choose DESCOVY?1,3,4
One pill, taken orally, once-daily, with no food requirements
Telehealth-compatible administration
Does not require individuals to come into the office for injections 6 times a year†
At-home HIV testing may be an option
May be started same day
Upon confirmation of HIV-negative test result
May be preferred by individuals fearful of needles
†Healthcare providers determine the number of appointments that are appropriate for individuals under their care and if those individuals should have in-person or remote visits.
